RESERPINE
LOE ApproachingNDAORALTABLET
Approved
Mar 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Just now · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Reserpine is an oral tablet small molecule antihypertensive agent approved in 1955 with an alkaloid origin. It was historically used to treat hypertension and certain psychiatric conditions by depleting catecholamine and serotonin stores in nerve terminals. The exact mechanism of action and current indications are not fully specified in available data.
LOE Approaching
This legacy product faces approaching loss of exclusivity with minimal commercial investment signaling a decline phase requiring defensive or transition-focused team strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on reserpine offers limited career advancement given its LOE-approaching status, minimal linked job openings, and declining commercial investment. This role is best suited for portfolio management, cost leadership, or transition planning experience rather than growth or innovation-focused career building.
Product Manager (legacy portfolio)Field Sales (niche markets only)
Worked on RESERPINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.